← ANALYST RATINGS · TIPRANKS
BioCryst (BCRX): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy2 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $19.25, the highest $32.00, the lowest $11.00. The average is +147.1% from the last price of $7.79.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $15.00 | Buy | +92.6% | Reiterated | 09.10.26on TipRanks 06:11 | +2.5%next day −2.2% · 5 days −6.9% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $11.00 | Hold | +41.2% | Reiterated | 08.10.26on TipRanks 21:45 | +2.5%next day −2.2% · 5 days −6.9% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $12.00 → $13.00+8.3% | Hold | +66.9% | Assigned | 30.09.26on TipRanks 07:35 | +0.9%next day −2.7% · 5 days −1.1% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $13.00 → $11.00−15.4% | Hold | +41.2% | Downgrade | 10.09.26on TipRanks 05:20 | −5.2%next day −2.9% · 5 days +4.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.50 | Hold | +22.0% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $9.50 | Hold | +22.0% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 | Hold | +22.0% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.00 → $9.50+5.6% | Hold | +22.0% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 | Hold | +22.0% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $9.50 → $9.00−5.3% | Hold | +15.5% | Reiterated | 09.09.26on TipRanks 09:05 | — | |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $16.00 | Buy | +105.4% | Reiterated | 08.09.26on TipRanks 13:15 | −8.4%next day −2.4% · 5 days −8.9% | ↗ |
| Unknown Analyst | Evercore ISI | $17.00 | Buy | +118.2% | Reiterated | 10.08.26on TipRanks Aug 14 21:04 | +4.9%next day +5.4% · 5 days +1.1% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $32.00 | Buy | +310.8% | Reiterated | 06.08.26on TipRanks 14:07 | +2.7%next day +0.2% · 5 days +4.3% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $20.00 | Buy | +156.7% | Reiterated | 06.08.26on TipRanks 08:50 | +2.7%next day +0.2% · 5 days +4.3% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | $30.00 | Buy | +285.1% | Reiterated | 05.08.26on TipRanks Aug 6 05:55 | +0.8%next day +2.7% · 5 days +16.4% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $15.00 | Buy | +92.6% | Reiterated | 15.07.26on TipRanks 06:40 | −3.8%next day −2.7% · 5 days +2.0% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $27.00 → $29.00+7.4% | Buy | +272.3% | Reiterated | 30.06.26on TipRanks 07:35 | +3.9%next day −3.4% · 5 days +11.3% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $25.00 → $28.00+12.0% | Buy | +259.4% | Reiterated | 07.05.26on TipRanks 05:55 | +1.1%next day −4.0% · 5 days +5.3% | ↗ |
| Gena Wang★★★★★★★★★★#4240 · hits 44% · avg +2.4% | Barclays | $11.00 → $9.00−18.2% | Hold | +15.5% | Reiterated | 03.11.25on TipRanks Nov 4 03:20 | −6.5%next day −0.3% · 5 days +5.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering BioCryst
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.25 at a price of $8.33 (+131.1%); now: $19.25 at $7.79 (+147.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 12 | 12 | 9 | 7 |
| Buy | 4 | 3 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.09 (from $-0.02 to $0.17). Last quarter: $0.30.
Sales
Next quarter’s sales estimate — $166M (from $162M to $170M). Last quarter: $218M.
Best top-analyst consensus in the sector · Healthcare
About BioCryst
- CEO: Charles K. Gayer
- Employees: 435
- 4505 Emperor Boulevard, Durham, NC, 27703, US
- www.biocryst.com
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Data from the stock’s TipRanks forecast page, read 54 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗